The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

LUPKIN: You know, it could, because the FDA just approved Zepbound as the first drug treatment for moderate to severe ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug ...